A mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity, its construction method and application
By combining doxorubicin injection and chronic stress stimulation in a mouse model, a model that can realistically simulate the cardiotoxicity of chemotherapy in cancer patients was constructed, solving the problem that existing models cannot reflect the effects of psychological stress, and realizing efficient assessment of early cardiac injury simulation and drug evaluation.
Patent Information
- Application Number
- CN202611402580.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-10
- Publication Date
- 2026-11-17
AI Technical Summary
Existing animal models cannot accurately simulate the cardiotoxicity of adriamycin chemotherapy in cancer patients under chronic psychological stress, which makes it impossible to explain the phenomenon of early cardiac damage at low doses and limits the development and evaluation of cardiovascular protective drugs.
A mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity was established by administering doxorubicin injections to mice on day 1 and subjecting them to chronic stress stimulation starting from day 1, with 4-6 hours of tubular restraint treatment per day for 7 days.
The study successfully simulated the pathological process of chronic stress exacerbating doxorubicin cardiotoxicity, shortened the modeling cycle, improved experimental efficiency, provided a more sensitive drug evaluation platform, and was able to truly reflect the cardiac response of clinical cancer patients.
Smart Images

Figure CN123101547A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medical biotechnology and relates to a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity, its construction method and application. Background Technology
[0002] Cancer and cardiovascular disease are two of the most serious threats to human health in today's society. Doxorubicin (DOX), as a representative of anthracycline antitumor antibiotics, is widely used clinically for the treatment of various solid tumors and hematological malignancies due to its broad-spectrum and potent antitumor properties. However, doxorubicin has severe, dose-dependent cardiotoxicity (DOX-induced cardiotoxicity, DIC). This cardiotoxicity can manifest as acute cardiac injury or delayed chronic dilated heart disease and heart failure, and its process is often irreversible with a very poor prognosis. This not only severely limits the cumulative clinical dosage of doxorubicin but also becomes the second leading cause of long-term morbidity and death in cancer survivors.
[0003] In real clinical settings, cancer patients often experience immense psychological stress during diagnosis, long-term treatment, and the uncertainty of the future (such as worry about a terminal illness, fear of death, and confusion about declining quality of life). This prolonged psychological pressure can lead to a state of chronic psychological stress. Existing medical research has confirmed that chronic stress can induce widespread physiological responses in the neuroendocrine and immune systems, playing a significant "cancer-promoting" role in tumor development, progression, and drug resistance. However, clinical observations have also shown that some patients exhibit significant heart failure even before doxorubicin reaches the traditional danger threshold dose. Researchers speculate that chronic psychological stress, as an important comorbidity factor, is highly likely to have a synergistic or additive effect with doxorubicin, thereby enhancing and prematurely inducing its cardiotoxicity. However, current research on whether and how chronic stress enhances disseminated intravascular coagulation (DIC) is extremely scarce.
[0004] A key bottleneck limiting the exploration of mechanisms and clinical translation in this field is the lack of preclinical animal models that can accurately simulate the dual impact of "psychological stress + chemical drug toxicity".
[0005] A search of existing patent literature and published academic research reveals that there are currently two main types of independent animal modeling techniques in this field, but neither can meet the above requirements: 1. Traditional Doxorubicin Cardiotoxicity Animal Models: Most current animal models of doxorubicin cardiotoxicity (DIC) employ a single doxorubicin administration route. For example, Chinese patent document CN114377025B (“Doxorubicin Chronic Heart Disease Mouse Model and Preparation Method”) discloses a method for establishing late-stage chronic heart disease caused by doxorubicin by intraperitoneal injection of 2 mg / kg doxorubicin weekly for 6 weeks followed by a 3-5 month drug withdrawal period in female BALB / c mice. Such conventional modeling methods, whether using acute high-dose injections or chronic long-term low-dose injections, treat only the “chemical drug (DOX)” as the sole pathogenic factor causing cardiac pathological changes, completely ignoring the crucial background condition of “chronic psychological stress” faced by clinical patients.
[0006] 2. Traditional chronic stress / stress-related models: Currently, existing chronic stress models (such as confinement stress, chronic unpredictable mild stress, etc.) are mostly used specifically for research on the mechanisms by which psychological stress promotes cancer. There are few reports of combined modeling with anti-tumor chemotherapy drugs (especially anthracyclines with specific cardiotoxicity).
[0007] In summary, the existing technology has the following obvious problems and shortcomings: Detached from real-world clinical applications, existing DIC models fail to fully simulate the physiological and pathological states: they neglect the psychological stress commonly experienced by cancer patients. Single-factor chemotherapy models cannot accurately reflect the complex systemic pathological network of "cancer diagnosis stress + chemotherapy drug toxicity" in clinical practice.
[0008] Unable to explain and simulate the clinical phenomena of low-dose / early cardiac injury: Traditional models typically require high doses of doxorubicin (e.g., 15-20 mg / kg cumulative dose) to induce significant decline in echocardiographic function and histological fibrosis in mice. This high-dose modeling masks the weakening effect of chronic stress on cardiac cell tolerance, making it difficult for researchers to verify the hypothesis that "psychological stress reduces the heart's tolerance threshold to DOX toxicity" in preclinical models.
[0009] The development of targeted cardiovascular protective drugs has been limited: the failure to take chronic psychological stress into account means that existing preclinical drug screening may not be able to fully assess the protective effect of drugs on the cardiovascular system under complex pathological conditions, and may easily miss potential therapeutic targets that target the "neuroendocrine stress-cardiotoxicity" cross pathway.
[0010] Therefore, there is an urgent need in this field for a mouse model with a reasonable modeling cycle, controllable operation procedures, and the ability to successfully simulate the pathological process of chronic stress exacerbating doxorubicin cardiotoxicity, as well as its preparation method. Summary of the Invention
[0011] Based on this, the purpose of this invention is to provide a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin. This model is an animal model that can realistically simulate clinical cancer patients receiving doxorubicin chemotherapy under "chronic stress." This animal model can be applied to the study of the pathogenesis of cardiotoxicity induced or aggravated by doxorubicin in clinical cancer patients under conditions of mental stress, as well as for the discovery of biomarkers and the evaluation of cardioprotective drugs.
[0012] This invention also provides a method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin. This method has a short modeling cycle, controllable conditions, and can successfully simulate the pathological process of chronic stress exacerbating doxorubicin cardiotoxicity.
[0013] To achieve the above objectives, the present invention adopts the following technical solution: This invention provides a method for constructing a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity. The process includes: injecting experimental mice with doxorubicin on day 1; and simultaneously administering chronic stress stimulation to the experimental mice starting from day 1 for 7 days, so as to obtain a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity with significantly impaired cardiac function on day 8.
[0014] Furthermore, the experimental mice were 5-6 week old male C57BL / 6J strain mice.
[0015] Furthermore, the doxorubicin can be administered via intraperitoneal injection.
[0016] Furthermore, the injection dose of the doxorubicin is calculated at 8-11 mg / kg body weight, preferably 8 mg / kg.
[0017] Furthermore, the chronic stress stimulation involves subjecting the mice to tubular restraint treatment daily.
[0018] Furthermore, the pipe restraint treatment is carried out for 4 to 6 hours per day.
[0019] The present invention further provides a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity, which is constructed using the above-mentioned method for constructing a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity.
[0020] Furthermore, on day 8, there was a significant decrease in left ventricular systolic fraction (FS%) and ejection fraction (EF%), and histological examination (H&E, Masson staining) showed a significant increase in cardiac fibrosis and damage.
[0021] The present invention further provides an application of the above-mentioned chronic stress combined with doxorubicin-induced cardiotoxicity mouse model in the study of the pathogenesis or biomarker discovery of cardiotoxicity induced or aggravated by doxorubicin in clinical cancer patients under mental stress.
[0022] The present invention further provides an application of the above-mentioned chronic stress combined with doxorubicin-induced cardiotoxicity mouse model in the evaluation of cardioprotective drugs that induce or aggravate cardiotoxicity by doxorubicin in clinical cancer patients under conditions of mental stress.
[0023] Compared with the prior art, the beneficial effects of the present invention are: 1. Highly aligned with real-world clinical pathophysiology, demonstrating significant clinical translational value. Existing animal models often focus solely on the chemical toxicity of doxorubicin, detached from the actual physiological context of clinical cancer patients. This invention, for the first time, incorporates the prevalent "chronic psychological stress" of clinical cancer patients into the modeling system, successfully simulating the cardiovascular damage pathological process under the dual impact of "chronic mental stress + chemotherapy drugs." This model more objectively and realistically reflects the body's response to chemotherapy in clinical cancer patients under anxiety and stress, significantly bridging the gap between basic research and clinical practice.
[0024] 2. The modeling cycle is extremely short, significantly saving time and economic costs, and greatly improving experimental efficiency. Existing doxorubicin chronic heart disease models typically require long-term, frequent administration and a waiting period of several months (e.g., 3-5 months after drug withdrawal) to develop typical cardiac fibrosis and decreased cardiac function. In contrast, the method of this invention is simple to operate, requiring only 8 days for the entire modeling cycle to obtain an ideal model with significantly reduced left ventricular systolic fraction (FS%) and ejection fraction (EF%), and increased cardiac tissue fibrosis. This greatly saves on animal husbandry time, labor costs, and research resources, significantly improving the efficiency of experimental progress.
[0025] 3. This invention provides the first confirmed and constructed research platform demonstrating how psychological stress reduces the cardiac drug tolerance threshold. Experimentally, this invention demonstrates that simple injection of low-dose doxorubicin (8 mg / kg) has little effect on cardiac function in mice, but the application of chronic conduit confinement pressure induces severe cardiac damage. This model effectively amplifies potential pathogenic factors, demonstrating for the first time in living animals that chronic pressure can significantly enhance the cardiotoxicity of doxorubicin. The establishment of this model fills a gap in animal models in this interdisciplinary field, providing a unique research platform for studying the mechanism of action of the complex axis of "neuroendocrine stress-chemotherapeutic drug cardiotoxicity."
[0026] 4. Providing a more sensitive evaluation system for the research and screening of novel cardiovascular protective drugs. Traditional models using high-dose doxorubicin (e.g., 14 mg / kg or higher) often result in acute and irreversible severe cardiac necrosis. This "destructive" model, due to its extreme damage, often masks the efficacy of early intervention drugs. The "low-dose DOX + pressure" two-factor modeling method used in this invention has a more hierarchical and physiologically significant damage mechanism, providing a more sensitive and reliable efficacy evaluation platform for screening multi-target drugs that combine anti-stress and anti-cardiotoxic effects (such as combination therapies targeting the autonomic nervous system, neuroendocrine system, and cardioprotective targets).
[0027] 5. The experimental conditions were rigorously designed and controllable, resulting in a high model success rate and good reproducibility. This invention innovatively subjected mice in the pressure-combined low-dose group to 4-6 hours of tubular restraint daily, while simultaneously subjecting other control group mice to the same duration of water and food deprivation. This rigorous quality control effectively eliminated confounding factors such as differences in food and water intake or metabolic changes, ensuring that the ultimately detected aggravated cardiac damage was purely attributed to "chronic mental stress," thus guaranteeing a very high success rate in model preparation and the reliability of experimental results. Attached Figure Description
[0028] To more clearly illustrate the technical solution of the present invention, the accompanying drawings used in the specific embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0029] Figure 1 This is a schematic diagram illustrating the method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin in an embodiment of the present invention; Figure 2 The figures show the open field experiment results of different mice in the embodiments and comparative examples of the present invention. In the figures, Figure A is a representative figure of the movement trajectory of different mice in the open field, and Figure B is an analysis figure of the ratio of the distance of different mice from the center of the open field to the total path. Figure 3 The figures show the results of light and dark box experiments on different mice in the embodiments and comparative examples of the present invention. In the figures, Figure A is a representative figure of the movement trajectory of different mice in the light box and the dark box, and Figure B is an analysis figure of the ratio of the movement distance of different mice in the light box to the total movement distance. Figure 4The figures show the echocardiographic results of different mice in the embodiments and comparative examples of the present invention. In the figures, A is a representative M-mode echocardiogram of different mice, B is an analysis of the left ventricular ejection fraction of different mice, C is an analysis of the left ventricular shortening fraction of different mice, and D is an analysis of the left ventricular output of different mice. Figure 5 The figures show the detection results of cardiac injury indicators in different mice in the embodiments and comparative examples of the present invention. In the figures, A is a representative image of H&E staining of cardiac tissue from different mice, B is a representative image of Masson staining of cardiac tissue from different mice, and C is a quantitative analysis of the proportion of fibrotic area in the Masson staining imaging results. Detailed Implementation
[0030] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. All mentioned embodiments are implemented based on the technical solutions of the present invention, and detailed implementation processes are given. However, it should be stated that the scope of protection of the present invention is not limited to the following embodiments.
[0031] Unless otherwise specified, the experimental methods used in the following experimental examples of this invention are conventional methods; the materials and reagents used are commercially available unless otherwise specified.
[0032] The method for constructing a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity in the following embodiments of the present invention is as follows: Figure 1 As shown, male C57BL / 6J mice were first administered a single intraperitoneal injection of doxorubicin (DOX) on day 1. Starting from day 1, they were then subjected to daily chloronic restraint stress (4–6 hours per day) for 7 days. On day 8, a chloronic restraint stress-induced cardiotoxicity mouse model with significantly impaired cardiac function was established. Echocardiography was performed on the mice on day 8, followed by euthanasia, and the heart and other tissues were harvested for model evaluation and validation.
[0033] Example 1
[0034] A mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity was constructed as follows: 1. Selection of experimental animals: 5-6 week old male C57BL / 6J mice were used; 2. Doxorubicin preparation and administration: Doxorubicin was dissolved in physiological saline to obtain doxorubicin injection solution. Administration was by intraperitoneal injection. On day 1 of the experiment, the doxorubicin injection solution was injected into mice. The dosage was a low dose of 8 mg / kg.
[0035] 3. Pressure Modeling: Starting from day 1 of the experiment, mice injected with doxorubicin were subjected to chronic pressure stimulation, and the mice were subjected to tubing restraint for 7 consecutive days. Specifically, a 50 mL centrifuge tube was prepared, and a hole was punched in the bottom of the tube to ensure free breathing for the mouse. The mouse was placed in the prepared 50 mL centrifuge tube, and cotton was used to secure it to prevent the mouse from moving inside the tube. The tubing restraint was performed for 4-6 hours each day for 7 days.
[0036] 4. On day 8, a mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity with significantly impaired cardiac function was obtained, which was designated as the stress combined with low-dose DOX (8 mg / kg) + stress group mouse model.
[0037] Comparative Example 1 This comparison is a blank control mouse model, and the treatment process is as follows: 1. Selection of experimental animals: 5-6 week old male C57BL / 6J mice were used; 2. Drug administration: The drugs were administered via intraperitoneal injection. On the first day of the experiment, physiological saline was injected into the mice.
[0038] 3. Fasting and water deprivation treatment: Starting from day 1 of the experiment, mice injected with doxorubicin were subjected to fasting and water deprivation treatment for 7 consecutive days, 4-6 hours per day.
[0039] 4. A blank control mouse model was obtained on day 8 and was designated as the blank control group (CON) mouse model.
[0040] Comparative Example 2 A mouse model treated with low-dose doxorubicin was constructed as follows: 1. Selection of experimental animals: 5-6 week old male C57BL / 6J mice were used; 2. Doxorubicin preparation and administration: Doxorubicin was dissolved in physiological saline to obtain doxorubicin injection solution. Administration was by intraperitoneal injection. On day 1 of the experiment, the doxorubicin injection solution was injected into mice. The dosage was a low dose of 8 mg / kg.
[0041] 3. Fasting and water deprivation treatment: Starting from day 1 of the experiment, mice injected with doxorubicin were subjected to fasting and water deprivation treatment for 4-6 hours per day for 7 consecutive days.
[0042] 4. A mouse model treated with low-dose doxorubicin was obtained on day 8 and designated as the low-dose DOX (8 mg / kg) mouse model.
[0043] Comparative Example 3 A mouse model of cardiotoxicity induced by high-dose doxorubicin was constructed as follows: 1. Selection of experimental animals: 5-6 week old male C57BL / 6J mice were used; 2. Doxorubicin preparation and administration: Doxorubicin was dissolved in physiological saline to obtain doxorubicin injection solution. Administration was by intraperitoneal injection. On day 1 of the experiment, the doxorubicin injection solution was injected into mice. The dosage was a high dose of 14 mg / kg.
[0044] 3. Fasting and water deprivation treatment: Starting from day 1 of the experiment, mice injected with doxorubicin were subjected to fasting and water deprivation treatment for 4-6 hours per day for 7 consecutive days.
[0045] 4. A mouse model of cardiotoxicity induced by high-dose doxorubicin was obtained on day 8 and designated as the high-dose DOX (14 mg / kg) mouse model.
[0046] Model Evaluation and Validation Behavioral tests and cardiac function and cardiac injury indicators were performed on the mouse models obtained in Example 1 and Comparative Examples 1-3, respectively. Echocardiography was performed on the mice on day 8, and then the mice were euthanized and their heart tissue was collected for model evaluation and validation.
[0047] 1. Behavioral Testing: Mice were restrained for 7 days, and their behavior was assessed using the open field test and the light-dark box test. The open field test was used to characterize whether mice in the chronic stress combined with doxorubicin treatment group were successfully induced to experience depression. The test results are as follows: Figure 2 As shown in the figure. The light-dark box test was used to characterize whether depression was successfully induced in mice treated with chronic stress combined with doxorubicin. The test results are shown in the figure. Figure 3 As shown.
[0048] The open field test can assess the level of depressive behavior in mice by measuring their movement trajectory in the open field and the ratio of the distance from the center of the open field to the total distance (Central / total distance). Mice that successfully develop a depression model usually exhibit reduced activity in the central area and tend to avoid the open field.
[0049] Figure 2Figure A in the figure represents the movement trajectories of different mice in an open field. As shown in the figure, the blank control (CON) group in Comparative Example 1 exhibited the widest range of movement trajectories, with a large number of mice traversing the central area of the open field, demonstrating ample autonomous exploration behavior. In Comparative Example 2, the mice in the low-dose DOX (8 mg / kg) single-dose group showed a slightly narrower range of movement, with a slightly decreased proportion of trajectories in the central area. Similarly, in Comparative Example 3, the mice in the high-dose DOX (14 mg / kg) single-dose group also showed a slightly more peripheral movement trajectory. Compared to the other comparative examples, the mice in Example 1, treated with a combination of stress and low-dose DOX (8 mg / kg) + stress, showed a significant concentration of movement trajectories towards the edges of the enclosure, with almost no trajectories in the central area, indicating a significant decrease in exploration willingness. This suggests that administering chronic stress stimulation to mice simultaneously with low-dose doxorubicin injection can successfully induce depression.
[0050] Figure 2 Figure B in the figure shows the ratio of the distance between the center of the open field and the total path for different mice. As can be seen from the figure, the proportion of the central trajectory in the control group (CON) of Comparative Example 1 was relatively high. In Comparative Example 2, the proportion of the central trajectory in the group treated with low-dose DOX (8 mg / kg) alone was not significantly different from that in the control group (CON) of Comparative Example 1 (ns). Similarly, in Comparative Example 3, the proportion of the central trajectory in the group treated with high-dose DOX (14 mg / kg) alone was not significantly different from that in the control group (CON) of Comparative Example 1 (ns). Compared to the other comparative examples, the proportion of the central trajectory in the group treated with stress combined with low-dose DOX (8 mg / kg) + stress in Example 1 was significantly reduced, showing a significant difference compared to the control group (CON) of Comparative Example 1 (*). This indicates that administering chronic stress stimulation to mice simultaneously with low-dose doxorubicin injection exacerbated anxiety-depressive-like behaviors in the mice.
[0051] The open field experiment results showed that DOX administration alone only slightly reduced the exploration level in the central region of mice, while the combination of drug and chronic stress stimulation significantly reduced the proportion of open field activity in mice, and spontaneous exploration behavior in mice was significantly reduced. A depression-like animal model was successfully constructed, verifying the effectiveness of the stress modeling protocol.
[0052] The light-dark box experiment relies on the mice's natural tendency to seek darkness and avoid light. The level of depressive behavior in mice is assessed by the movement trajectory of mice in the light box and the dark box, as well as the ratio of the distance the mouse travels in the light box to the total distance (light / total distance). Mice that successfully develop a depression model usually show a significant reduction in the time spent in the light box and the distance they travel.
[0053] Figure 3 Figure A in the figure represents the movement trajectories of different mice in the light and dark boxes. As shown in the figure, the blank control (CON) group in Comparative Example 1 exhibited numerous movement trajectories in both the light and dark boxes, with a high frequency of movement between the two areas, indicating a strong desire to explore. In Comparative Example 2, the number of movement trajectories in the light box decreased slightly in the group treated with low-dose DOX (8 mg / kg) alone, while the distribution of movement in both the light and dark boxes showed no significant shift. In Comparative Example 3, the distribution of movement trajectories in both the light and dark boxes in the group treated with high-dose DOX (14 mg / kg) alone was similar to that in the blank control group in Comparative Example 1, and the level of exploration in the light box did not show a significant decrease. Compared to the various comparative examples, the movement trajectories of the mice in Example 1, treated with a combination of pressure and low-dose DOX (8 mg / kg) + stress, were concentrated in the dark box area, while movement trajectories in the light box were sparse, indicating that the mice clearly avoided bright environments.
[0054] Figure 3 Figure B in the figure shows the ratio of the distance traveled in the test chamber to the total distance traveled in different groups of mice. As shown in the figure, the baseline level was observed in Comparative Example 1 (the blank control group, CON); the proportions of distance traveled in the test chamber in Comparative Example 2 (the group treated with low-dose DOX (8 mg / kg) alone) and Comparative Example 3 (the group treated with high-dose DOX (14 mg / kg) alone) were similar to those in the CON group, with no statistically significant difference among the three groups (ns); compared with the CON group, the proportion of distance traveled in the test chamber in the group treated with pressure combined with low-dose DOX (8 mg / kg) + stress in Example 1 was significantly reduced, with a statistically significant difference (**).
[0055] The results of the light-dark box experiment showed that DOX administration alone did not significantly change the light-dark exploration preference of mice, while the combination of drug and chronic stress stimulation significantly induced the behavior of mice to seek darkness and avoid light, significantly reduced the activity distance in the light box, and significantly increased the depressive-like mood of mice. This indicates that the stress combined with low-dose DOX treatment successfully induced depression in mice.
[0056] 2. Cardiac Function Indicator Testing: On day 7 after drug administration, thoracic echocardiography was performed on mice using a Vevo 3100 instrument to obtain cardiac function indicators such as ejection fraction (EF%), fractional shortening (FS%), and cardiac output (CO). The test results are as follows: Figure 4 As shown.
[0057] Figure 4Figure A in the figure shows representative M-mode echocardiogram images of mice from different groups. As can be seen from the figure, in Comparative Example 1, the blank control (CON) group of mice showed full ventricular wall motion amplitude and regular ventricular wall systolic and diastolic rhythms; in Comparative Example 2, the low-dose DOX (8 mg / kg) group alone showed no obvious abnormalities in ventricular wall motion, and cardiac function was not significantly changed compared with the CON group; as a positive control, Comparative Example 3, the high-dose DOX (14 mg / kg) group alone showed significantly reduced cardiac function, with weakened ventricular wall motion and impaired cardiac contractile function; compared with each comparative example, in Example 1, the pressure combined with low-dose DOX (8 mg / kg) + stress treatment group of mice showed significantly reduced ventricular wall motion amplitude, significantly increased end-systolic ventricular diameter, and decreased cardiac contractile capacity.
[0058] Figure 4 Figure B in the figure shows the analysis of left ventricular ejection fraction (EF) in mice of different groups. As can be seen from the figure, the control group (CON) in Comparative Example 1 maintained a high EF level, while the control group (CON) remained at baseline. In Comparative Example 2, the EF of the low-dose DOX (8 mg / kg) group was not significantly different from that of the CON group (ns). As a positive control, the EF of the high-dose DOX (14 mg / kg) group in Comparative Example 3 was significantly lower than that of the CON group, with a statistically significant difference (**). Compared with the other comparative examples, the EF of mice in the stress combined with low-dose DOX (8 mg / kg) + stress treatment group in Example 1 showed a highly significant decrease: the difference was extremely significant compared with the CON group (***), statistically significant compared with the low-dose DOX group in Comparative Example 2 (**), and not significantly different compared with the high-dose DOX group in Comparative Example 3 (ns).
[0059] Figure 4 Figure C in the figure is an analysis of the fractional shortening (FS) of the left ventricle in different mice. As can be seen from the figure, the trend of FS differences in each group of mice is completely consistent with that of EF.
[0060] Figure 4Figure D in the figure shows the analysis of left ventricular output (cardiac output) in mice of different groups. As can be seen from the figure, the left ventricular output of the control group (CON) in Comparative Example 1 was at the baseline level. The left ventricular output of the low-dose DOX (8 mg / kg) group in Comparative Example 2 was slightly lower than that of the CON group, but there was no significant difference between the groups (ns). As a positive control, the left ventricular output of the high-dose DOX (14 mg / kg) group in Comparative Example 3 was significantly lower than that of the CON group, and the difference was extremely significant (***). Compared with the comparative examples, the left ventricular output of mice in Example 1, which was treated with pressure combined with low-dose DOX (8 mg / kg) + stress, was extremely significantly reduced: the difference was extremely significant (***) compared with the CON group, and the decrease was comparable to that of the high-dose DOX group in Comparative Example 3, with no significant difference (ns), indicating that the cardiac pumping ability of mice in both groups was significantly impaired.
[0061] The results of cardiac function tests showed that administration of a low dose of DOX (8 mg / kg) alone did not cause significant damage to cardiac function in mice. However, the addition of chronic pressure stimulation to the low-dose DOX significantly inhibited left ventricular systolic function in mice, resulting in a significant decrease in ejection fraction, fractional shortening, and cardiac output, as well as a decline in cardiac systolic and diastolic capacity, with results comparable to those of a high dose of DOX (14 mg / kg). Chronic pressure stimulation synergistically exacerbated cardiac dysfunction in mice with DOX.
[0062] 3. Detection of cardiac injury indicators: Seven days after drug administration, mouse heart tissue samples were collected for HE and Masson tests. The test methods are as follows, and the test results are as follows. Figure 5 As shown.
[0063] H&E staining method: Fix the paraffin block on the microtome and set the section thickness to 5µm. After trimming to the target tissue level, collect the sections and gently float them on water with a brush to allow them to unfold naturally. Use a clean glass slide to retrieve the fully unfolded sections, drain the water, and place them in a slide box. Bake in a 60℃ oven for 2 hours. Dewax the paraffin sections with xylene, then rehydrate by washing with ethanol and water in different proportions. Stain with hematoxylin for 2 minutes, wash with water, differentiate with differentiation solution for approximately 3-5 seconds, rinse with tap water for 10 minutes, stain with eosin for 1 minute, rinse with tap water for 10 minutes, and dehydrate sequentially with 95% EtOH (2 minutes) and 100% EtOH (2 minutes) before mounting. Image using a Nikon upright microscope.
[0064] Masson staining assay: Dewaxed mouse heart sections were stained with Weigert iron hematoxylin using the Masson trichrome staining kit (Solarbio, GI1340) for 5-10 min, followed by washing with distilled water to remove excess stain. Acidic ethanol differentiation solution was then added, followed by washing with water and re-blueing with Masson blue solution for 3-5 min, then washing with distilled water for 30 s. Next, Ponceau S and fuchsin staining solutions were added for 5-10 min, followed by washing with weakly acidic working solution for 30 s, and excess liquid was discarded. Phosphomolybdic acid solution was added for 1-2 min, followed by discarding excess liquid, and then aniline blue staining solution was added for 1-2 min, followed by washing with weakly acidic working solution for 30 s. Finally, the sections were dehydrated sequentially with 95% ethanol and anhydrous ethanol, cleared twice with xylene, mounted with neutral resin, and observed and photographed under a Nikon upright microscope. The images were used to quantify the area of fibrotic regions and the total area using ImageJ software, and statistical analysis was performed using GraphPad Prism 10.
[0065] Figure 5 Figure A in the figure shows representative H&E staining images of different mouse heart tissues. As can be seen from the figure, in Comparative Example 1, the blank control (CON) group mice showed neat and orderly arrangement of heart fibers, clear and complete striations, regular heart cell morphology, uniform cytoplasm, and no vacuolar degeneration. In Comparative Example 2, the heart cell structure of the mice treated with low-dose DOX (8 mg / kg) alone was basically intact, with only a few heart cells showing slight morphological changes and no obvious cardiac damage. Compared to Comparative Examples 1 and 2, the heart cells in the pressure combined with low-dose DOX (8 mg / kg) + stress treatment group in Example 1 and the high-dose DOX (14 mg / kg) treatment group in Comparative Example 3 showed disordered arrangement and loss of normal polarity, with round vacuoles of varying sizes and clear boundaries appearing in the cytoplasm, indicating significant cell damage.
[0066] Figure 5Figures B and C in the figure are representative images of Masson staining of different mouse heart tissues (collagen fibers appear blue and heart tissue appears red in Masson staining) and quantitative analysis of the percentage of fibrotic area (%), respectively. As shown in the figures, the blank control (CON) group mice in Comparative Example 1 showed only a small amount of blue collagen deposition in the cardiac interstitium, indicating extremely low fibrosis. The cardiac fibrosis area in the mice in Comparative Example 2 treated with low-dose DOX (8 mg / kg) alone was not significantly different from that in Comparative Example 1. Compared to Comparative Examples 1 and 2, the percentage of fibrotic area in the hearts of mice treated with pressure combined with low-dose DOX (8 mg / kg) + stress in Example 1 and mice treated with high-dose DOX (14 mg / kg) alone in Comparative Example 3 was significantly increased, indicating that low-concentration DOX combined with pressure, or high-concentration DOX, can induce cardiac fibrosis.
[0067] Based on the above model evaluation and validation results, this invention successfully constructs a cardiovascular injury model of "chronic mental stress + low-dose DOX" by introducing the common chronic psychological stress of cancer patients into the modeling system. This model more realistically simulates the stress state of the body during clinical chemotherapy, narrowing the gap between basic research and clinical practice. The model is simple to operate, with a modeling cycle of only 8 days. It can significantly reduce left ventricular systolic fraction (FS%) and ejection fraction (EF%), and exacerbate cardiac fibrosis, greatly saving animal husbandry time, manpower, and research resources, and improving experimental efficiency. Unlike the acute irreversible cardiac necrosis caused by traditional high-dose DOX (≥14 mg / kg), this method uses low-dose DOX combined with stress stimulation, resulting in a more hierarchical and physiologically significant injury mechanism, avoiding the masking of early intervention efficacy due to excessive damage. This model provides a more sensitive and reliable efficacy evaluation platform for screening multi-target drugs that combine anti-stress and anti-cardiotoxic effects (such as combined drugs that regulate the autonomic nervous system, neuroendocrine system, and cardioprotective targets).
[0068] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin, characterized in that, The procedure included: injecting doxorubicin into the experimental mice on day 1; and simultaneously administering chronic stress stimulation to the experimental mice starting from day 1 for 7 days, resulting in a mouse model of chronic stress combined with doxorubicin cardiotoxicity with significantly impaired cardiac function on day 8.
2. The method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin according to claim 1, characterized in that, The experimental mice were 5-6 week old male C57BL / 6J strain mice.
3. The method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin according to claim 1, characterized in that, The doxorubicin is administered via intraperitoneal injection.
4. The method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin according to claim 1, characterized in that, The injection dose of doxorubicin is calculated as 8-11 mg / kg body weight.
5. The method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin according to claim 1, characterized in that, The chronic stress stimulation involved subjecting the mice to tubular restraint treatment daily.
6. The method for constructing a mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin according to claim 5, characterized in that, The pipe restraint treatment is carried out for 4 to 6 hours per day.
7. A mouse model of cardiotoxicity induced by chronic stress combined with doxorubicin, characterized in that, The mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity was constructed using the method described in any one of claims 1 to 6.
8. A mouse model of chronic stress combined with doxorubicin-induced cardiotoxicity according to claim 7, characterized in that, On day 8, there was a significant decrease in left ventricular systolic fraction and ejection fraction, and histological examination showed a significant increase in cardiac fibrosis and damage.
9. The application of the chronic stress combined with doxorubicin-induced cardiotoxicity mouse model as described in any one of claims 7 or 8 in the study of the pathogenesis or biomarker discovery of cardiotoxicity induced or aggravated by doxorubicin in clinical cancer patients under conditions of mental stress.
10. The use of the chronic stress combined with doxorubicin-induced cardiotoxicity mouse model as described in any one of claims 7 or 8 in the evaluation of cardioprotective drugs that induce or aggravate cardiotoxicity by doxorubicin in clinical cancer patients under conditions of mental stress.
Citation Information
Patent Citations
Adriamycin chronic cardiomyopathy mouse model and preparation method
CN114377025B
